Biocept, Inc. (BIOC): Price and Financial Metrics
BIOC Price/Volume Stats
Current price | $0.43 | 52-week high | $27.00 |
Prev. close | $0.50 | 52-week low | $0.32 |
Day low | $0.40 | Volume | 751,400 |
Day high | $0.49 | Avg. volume | 764,067 |
50-day MA | $1.06 | Dividend yield | N/A |
200-day MA | $6.35 | Market Cap | 1.14M |
BIOC Stock Price Chart Interactive Chart >
Latest BIOC News From Around the Web
Below are the latest news stories about BIOCEPT INC that investors may wish to consider to help them evaluate BIOC as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start off the workweek with a detailed breakdown of the biggest pre-market stock movers for Monday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic worth checking out on Wednesday and we have all the latest news happening this morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayPre-market stock movers are a hot topic among traders on Thursday and we're offering all of the latest coverage this morning! |
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal MetastasesSAN DIEGO, September 21, 2023--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept’s proprietary CNSide assay in monitoring the response to therapy of LM, a |
Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?Biocept Inc (NASDAQ: BIOC) shares are trading higher after the company signed a non-exclusive licensing agreement for CNSide with Plus Therapeutics Inc (NASDAQ: PSTV), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Benzinga exclusively broke the story. Plus Therapeutics is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal m |
BIOC Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | -65.60% |
1-year | -95.90% |
3-year | -99.72% |
5-year | -99.88% |
YTD | N/A |
2023 | 0.00% |
2022 | -85.36% |
2021 | -18.47% |
2020 | 55.24% |
2019 | -66.74% |
Continue Researching BIOC
Want to see what other sources are saying about Biocept Inc's financials and stock price? Try the links below:Biocept Inc (BIOC) Stock Price | Nasdaq
Biocept Inc (BIOC) Stock Quote, History and News - Yahoo Finance
Biocept Inc (BIOC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...